Azenta Inc (AZTA)vsNovartis AG ADR (NVS)
AZTA
Azenta Inc
$22.69
-0.66%
HEALTHCARE · Cap: $1.05B
NVS
Novartis AG ADR
$148.38
-2.52%
HEALTHCARE · Cap: $289.19B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 9385% more annual revenue ($56.58B vs $596.48M). NVS leads profitability with a 23.9% profit margin vs -29.1%. AZTA appears more attractively valued with a PEG of 0.53. AZTA earns a higher WallStSmart Score of 56/100 (C).
AZTA
Buy56
out of 100
Grade: C
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+31.0%
Fair Value
$44.14
Current Price
$22.69
$21.45 discount
Margin of Safety
-65.2%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 8778.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
1.0% revenue growth
Smaller company, higher risk/reward
ROE of -11.5% — below average capital efficiency
Currently unprofitable
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZTA
The strongest argument for AZTA centers on Price/Book, EPS Growth, Debt/Equity. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : AZTA
The primary concerns for AZTA are Revenue Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
AZTA profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
AZTA carries more volatility with a beta of 1.40 — expect wider price swings.
AZTA is growing revenue faster at 1.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
AZTA scores higher overall (56/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Azenta Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Azenta Inc. is a leading provider of sample management solutions and life science tools focused on improving laboratory efficiencies for biotechnology and pharmaceutical sectors. The company specializes in innovative automation, comprehensive biorepository services, and advanced storage technologies, empowering clients to expedite drug discovery while ensuring compliance with regulatory standards. With a robust strategy centered on cutting-edge technology and strategic collaborations, Azenta is strategically positioned to capitalize on growth opportunities within the expanding global life sciences market, thereby reinforcing its competitive edge in biobanking and sample management. Its unwavering commitment to advancing scientific research through sophisticated products further enhances its appeal to institutional investors seeking exposure to the dynamic life sciences landscape.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?